Dr. Straubinger received dual B.A. degrees in English and Anthropology from the University of Rochester, the M.S. degree in Natural Sciences from the Roswell Park division of the University at Buffalo/SUNY, and the Ph.D. in Pharmacology from the University of California at San Francisco. He was a postdoctoral fellow in the Cancer Research Institute and in the Cardiovascular Research Institute at the University of California, San Francisco.
Dr. Straubinger's research focuses on the broad area of drug carriers and drug delivery, with an emphasis on the mechanisms by which drug carriers alter the pharmacology of carrier-associated drugs. The research approaches include biophysical investigations of the pharmaceutical properties of drug:carrier complexes, pharmacokinetic and pharmacodynamic analysis to probe mechanisms behind the therapeutic effects of drug carriers. A major new research direction is to develop proteomic approaches, principally based on liquid chromatography/mass spectrometry (LC/MS), to identify pharmacodynamic effect 'biomarkers' to assist in the development and optimization of therapies. Current research funding focuses on mechanisms by which drug carriers can modulate tumor vascular permeability.
|
Address:
539 Cooke Hall, North Campus Telephone: (716) 645-2844 ext. 243 Fax: (716) 645-3693 |
Customized/Personal links [private] Upload/Download area (private- for collaborators only) |
CLICK HERE for an updated bibliograpy (limited to articles listed in the MEDLINE database).
1. Qu J; Jusko WJ; Straubinger RM. Utility of cleavable isotope coded affinity tagged reagents for quantification of low-copy proteins induced by methylprednisolone using liquid chromatography/tandem mass spectrometry. Analyt. Chem. 78: 4543-52 (2006).
2. Arnold RD; Mager DE; Slack JE; Straubinger RM. Effect of repetitive administration of doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin. Cancer Res. 11: 8856-65 (2005).
3. Qu J; Straubinger RM. Improved sensitivity for quantification of proteins using triply charged cleavable isotope-coded affinity tag (cICAT) peptides. Rapid Commun. Mass Spect. 19: 2857-64 (2005).
4. Straubinger RM; Balasubramanian SV. Preparation and characterization of taxane-containing liposomes. In (N Duzgunes ed.), Methods in Enzymology, 391, Academic Press, New York, 2005, pp. 97-117.
5. Arnold RD; Slack JE; Straubinger RM. Quantification of doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/ electrospray tandem mass spectroscopy. J. Chromatog. B, Anl. Tech. Biomed. Life Sci. 808: 141-52 (2004).
6. Straubinger R; Arnold R; Zhou R; Mazurchuk R; Slack J. Antivascular and antitumor activities of liposome-associated drugs. Anticancer Res. 24: 397-404 (2004).
7. Duzgunes N; Bagatolli LA; Meers PR; Oh Y-K; Straubinger RM. Fluorescence methods in liposome research. In (VP Torchilin and V Weissig ed.), Liposomes: A Practical Approach, Oxford University Press, Oxford, UK, 2003, pp. 105-47.
8. Fetterly GJ; Straubinger RM. Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS PharmSci 5: Article 31 (2003).
9. Almon R; DuBois D; Brandenburg E; Shi W; Zhang S; Straubinger R; Jusko W. Pharmacodynamics and pharmacogenomics of diverse receptor-mediated effects of methylprednisolone in rats using microarray analysis. J. Pharmacokinet. Pharmacodynam. 29: 103-29 (2002).
10. Balasubramanian SV; Campbell RB; Straubinger RM. Propofol, a general anesthetic, promotes the formation of fluid phase domains in model membranes. Chem. Phys. Lipids 114: 35-44 (2002).
11. Lorenz S; Bigwarfe JPM; Balasubramanian SV; Fetterly GJ; Straubinger RM; Wood TD. Noncovalent dimerization of paclitaxel in solution: Evidence from electrospray ionization mass spectrometry. J. Pharm. Sci. 91: 2057-66 (2002).
12. Zhou R; Mazurchuk RV; Straubinger RM. Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res. 62: 2561-6 (2002).
13. Campbell RB; Balasubramanian SV; Straubinger RM. Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes. J. Pharm. Sci. 90: 1091-105 (2001).
14. Campbell RB; Balasubramanian SV; Straubinger RM. Phospholipid-cationic lipid interactions: Influences on membrane and vesicle properties. Biochim. Biophys. Acta 1512: 27-39 (2001).
15. Fetterly GJ; Tamburlin JM; Straubinger RM. Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model. Biopharm. Drug Dispos. 22: 251-61 (2001).
16. Balasubramanian SV; Bruenn J; Straubinger RM. Liposomes as formulation excipients for protein pharmaceuticals: a model protein study. Pharm. Res. 17: 344-50 (2000).
17. Mazurchuk R; Zhou R; Straubinger RM; Chau RI; Grossman Z. Functional magnetic resonance (fMR) imaging of a rat brain tumor model: implications for evaluation of tumor microvasculature and therapeutic response. Magn. Reson. Imag. 17: 537-48 (1999).
18. Edgerton M; Koshlukova SE; Lo TE; Chrzan BG; Straubinger RM; Raj PA. Candidacidal activity of salivary histatins. Identification of a histatin 5-binding protein on Candida albicans. J. Biol. Chem. 273: 20438-47 (1998).
19. Sharma US; Sharma A; Chau RI; Straubinger RM. Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm. Res. 14: 992-8 (1997).
20. Oh Y-K; Nix DE; Straubinger RM. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular M. avium infection. Antimicrob. Agents Chemother. 39: 2104-11 (1995).
21. Sharma A; Straubinger RM; Ojima I; Bernacki RJ. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. J. Pharm. Sci. 84: 1400-4 (1995).
22. Sharma US; Balasubramanian SV; Straubinger RM. Pharmaceutical and physical properties of paclitaxel (taxol) complexes with cyclodextrins. J. Pharm. Sci. 84: 1223-30 (1995).
23. Sharma A; Conway WD; Straubinger RM. Reversed-phase high-performance liquid chromatographic determination of taxol in mouse plasma. J. Chromatog. B, Anl. Tech. Biomed. Life Sci. 655: 315-9 (1994).
24. Sharma A; Mayhew E; Straubinger RM. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res. 53: 5877-81 (1993).
25. Straubinger RM; Papahadjopoulos D; Hong K; Endocytosis and intracellular fate of liposomes using Pyranine as a probe. Biochemistry 29: 4929-39, 1990.
26. Straubinger RM; Lopez NG; Debs R; Hong K; Papahadjopoulos D; Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively-charged and antibody-targeted liposomes. Cancer Res. 48: 5237-45, 1988.
27. Debs R, Straubinger RM, Brunette E, Lin J, Lin E, Papahadjopoulos D: Selective enhancement of pentamidine accumulation in the lung by administration in liposomes via aerosol and intravenous routes. Amer. Rev. Rep. Dis., 135:731-737, 1987.
28. Straubinger RM, Duzgunes N, Papahadjopoulos D: pH-Sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. FEBS Letters, 179:148-154, 1985.
29. Straubinger RM, Hong K, Friend DS, Papahadjopoulos D: Endocytosis of liposomes and intracellular fate of encapsulated contents: encounter with a low-pH compartment after internalization in coated vesicles. Cell, 32:1069-1079, 1983.